Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study
BMC Cancer, December 2018, 18:770
Marie Viala, Akiko ChibaSimon ThezenasLaure DelmondPierre-Jean LamySarah L. MottMary C. SchroederAlexandra ThomasWilliam Jacot
- Breast Cancer Mortality reduced 60 percent if more than 60 ng of Vitamin D – meta-analysis June 2017
- Breast Cancer treatment outcome might be predictable from Vitamin D test results – trial 2024
- Breast Cancer 80 percent less likely if high level of vitamin D – June 2018
- Breast Cancer Awareness month should be changed to PREVENTION – video Aug 2018
YouTube Video - 1 minute long by www.VDDKills.com
Download the PDF from VitaminDWiki
pCR = pathologic Complete Response
There has been interest in the potential benefit of vitamin D (VD) to improve breast cancer outcomes. Pre-clinical studies suggest VD enhances chemotherapy-induced cell death. Vitamin D deficiency was associated with not attaining a pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) for operable breast cancer. We report the impact of VD on pCR and survival in an expanded cohort.
Patients from Iowa and Montpellier registries who had serum VD level measured before or during NAC were included. Vitamin D deficiency was defined as < 20 ng/mL. Pathological complete response was defined as no residual invasive disease in the breast and lymph nodes. Survival was defined from the date of diagnosis to the date of relapse (PFS) or date of death (OS).
The study included 327 women. Vitamin D deficiency was associated with the odds of not attaining pCR (p = 0.04). Fifty-four patients relapsed and 52 patients died. In multivariate analysis, stage III disease, triple-negative (TN) subtype and the inability to achieve pCR were independently associated with inferior survival. Vitamin D deficiency was not significantly associated with survival in the overall sample; however a trend was seen in the TN (5-years PFS 60.4% vs. 72.3%, p = 0.3), and in the hormone receptor positive /human epidermal growth factor receptor 2 negative (HER2-) subgroups (5-years PFS 89% vs 78%, p = 0.056).
Vitamin D deficiency is associated with the inability to reach pCR in breast cancer patients undergoing NAC.